![Ipamorelin [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/ipamorelin.jpg)
$55.00
Ipamorelin is an investigational growth hormone secretagogue studied for its effects on growth hormone release. Evidence for long-term subcutaneous use and body-composition outcomes is limited. Research use only; not for human or animal consumption.
For laboratory research only. Not for human or animal consumption.
VIP Peptides · Research Compound
Ipamorelin is a synthetic growth hormone secretagogue studied for its
interaction with the growth hormone secretagogue receptor. This
profile covers the 10 mg product version; it is not an FDA-approved
medicine.
Product Information
Ipamorelin is a synthetic peptide studied for its activity at the
growth hormone secretagogue receptor, GHSR-1a. Research has
examined whether receptor activation can stimulate growth hormone
release from the pituitary.
Ipamorelin has been described as selective in some research
settings. Selectivity does not establish long-term safety or prove
that it avoids effects on other hormone pathways in every person
or with every product.
This profile covers the 10 mg vial version. Confirm product
identity and quantity against the label and matching batch
documentation.
| Product | Ipamorelin |
|---|---|
| Compound type | Growth hormone secretagogue peptide |
| Receptor studied | Growth hormone secretagogue receptor (GHSR-1a) |
| Product quantity | 10 mg, as stated on product label |
| Research focus | Growth hormone release and related pathways |
| Regulatory status | Investigational; not FDA-approved |
| Use classification | Research use only |
Research Areas
Human pharmacology research has examined ipamorelin’s effect on
growth hormone release. These findings do not establish long-term
benefits for body composition, recovery or healthy aging.
Lean-mass, recovery and fat-metabolism claims are not established
by robust long-term clinical trials of subcutaneous ipamorelin.
Outcomes observed in research should not be treated as expected
results for this product.
Intravenous ipamorelin has been studied in a postoperative gastric
motility setting. Results from that specific route and clinical
context do not establish safety or effectiveness for subcutaneous
use or other purposes.
Evidence Overview
Much of the human data involves short-term intravenous research.
Evidence for long-term subcutaneous use, body-composition outcomes
and anti-aging claims is limited.
FDA notes limited safety information for certain injectable routes
and describes serious adverse events, including deaths, in a study
where ipamorelin was administered intravenously for gastric
motility. That report does not by itself establish the risk for
every route or product, but it means broad safety claims are
not supported.
Safety & Regulatory Status
Ipamorelin is not FDA-approved for any indication. FDA has described
potential immunogenicity concerns for compounded ipamorelin acetate,
including aggregation and peptide-related impurities, and says there
is insufficient safety information for certain injectable routes.
Ipamorelin is prohibited under the 2026 WADA Prohibited List.
Athletes should check the rules that apply to their sport and
organization.
Research-grade material is not an approved medicine. Product
identity, purity and sterility can vary between suppliers.
Age & Policy Confirmation
Please confirm your age and review the policies before entering.
![GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) [100mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/ghk-300x300.jpg)
![Epitalon [50mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/epitalon-1-300x300.jpg)
![KPV (Lysine-Proline-Valine) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/kpv-300x300.jpg)
![GLOW [70mg] (GHK-Cu | BPC-157 | TB-500)](https://vipresearchpeptides.com/wp-content/uploads/2026/10/glo-300x300.jpg)
Reviews
There are no reviews yet.